Prevalence and frequencies of human papilloma virus types in adenocarcinoma in situ of the uterine cervix.
10.3760/cma.j.cn112151-20210817-00578
- Author:
Jun JIN
1
;
Rong Kui LUO
2
;
Jing ZHAO
1
;
Yan NING
1
;
Yu Qing QU
1
;
Xiang TAO
1
;
Xian Rong ZHOU
1
Author Information
1. Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.
2. Department of Pathology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
- Publication Type:Journal Article
- MeSH:
Adenocarcinoma in Situ/epidemiology*;
Adult;
Aged;
Aged, 80 and over;
Female;
Human papillomavirus 16/genetics*;
Human papillomavirus 18/genetics*;
Humans;
Middle Aged;
Papillomaviridae/genetics*;
Papillomavirus Infections/diagnosis*;
Prevalence;
Uterine Cervical Neoplasms/pathology*;
Young Adult
- From:
Chinese Journal of Pathology
2022;51(4):338-343
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To examine the prevalence and frequencies of human papillomavirus (HPV) genotypes in cervical adenocarcinoma in situ (AIS). Methods: The cases of cervical AIS with concurrent tests of cytology and HPV typing from January 2007 to February 2020 in the Obstetrics and Gynecology Hospital of Fudan University were collected and analyzed. Results: A total of 478 cases of cervical AIS were obtained. The average age of the patients was 39.4 years (range, 19-81 years). The largest age group was 30-39 years (44.8%), followed by 40-49 years (34.7%). Among the 478 patients, 355 underwent high-risk HPV (hrHPV) testing and had a hrHPV-positive rate of 93.8%. Of the 355 patients, 277 also underwent HPV typing and were mostly positive for either or both HPV16 and HPV18 (93.1%), with 55.6% positive for HPV18 and 48.7% positive for HPV16. Among the 478 cases, 266 cases (55.6%) were diagnosed with both AIS and squamous intraepithelial lesion (SIL), while 212 cases (44.4%) were diagnosed with only AIS. Patients infected with HPV16 in the AIS and SIL group significantly outnumbered those in the AIS alone group (P<0.05). Moreover, the rate of positive cytology was 55.9% (167/299 cases), while that of negative cytology was 44.1% (132/299). Among the 109 patients with negative cytology results and co-tested hrHPV, there were 101 HPV-positive cases (92.7%), of which 88 cases were subject to HPV typing and showed an HPV16/18 positive rate of 94.3% (83/88 cases). Conclusions: The combination of HPV typing and cytological screening can maximize the detection rate of cervical AIS, and should continue to be utilized, ideally on a larger scale, in the future.
